[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Mink Therapeutics Inc (INKT)

Mink Therapeutics Inc (INKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,313
  • Shares Outstanding, K 4,966
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,490 K
  • EBIT $ -13 M
  • EBITDA $ -12 M
  • 60-Month Beta 0.35
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.77
  • Number of Estimates 1
  • High Estimate $-0.77
  • Low Estimate $-0.77
  • Prior Year $-0.70
  • Growth Rate Est. (year over year) -10.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.48 +26.53%
on 03/24/26
14.88 -27.89%
on 04/17/26
+1.91 (+21.66%)
since 03/23/26
3-Month
8.48 +26.53%
on 03/24/26
16.93 -36.61%
on 03/10/26
-1.77 (-14.16%)
since 01/23/26
52-Week
6.34 +69.24%
on 05/12/25
76.00 -85.88%
on 07/11/25
+3.12 (+41.00%)
since 04/23/25

Most Recent Stories

More News
MiNK Therapeutics Reports Phase II Data on Immune Reprogramming and Durable Survival in PD-1 Refractory Gastroesophageal Cancer

First study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in gastroesophageal cancer shows disease control rate (DCR) in 77% of patients and long-term survival beyond 20 months in a subset of...

INKT : 10.73 (-5.38%)
MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026

Study will highlight novel iNKT cell-based combinations in checkpoint-refractory disease Data expected to inform immune modulation, treatment sequencing strategy, and clinical durability of response ...

INKT : 10.73 (-5.38%)
MiNK Therapeutics to Present New Data at ASGCT 2026 Highlighting Context-Dependent Activity of iNKT Cell Therapy

NEW YORK, April 02, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc.  (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...

INKT : 10.73 (-5.38%)
MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc.  (NASDAQ: INKT ), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell...

INKT : 10.73 (-5.38%)
MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum

ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data by year end; market opportunity of ~200,000–300,000 patients annually in US/EU C-Further Consortium collaboration adds to growing...

INKT : 10.73 (-5.38%)
MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics , Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies...

INKT : 10.73 (-5.38%)
MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers

Selected as a C-Further program with up to ~$1.1 million in non-dilutive, aggregate payments to advance IND-enabling development, with potential for meaningful double-digit downstream commercial revenue...

INKT : 10.73 (-5.38%)
MiNK Therapeutics Presents New Data of allo-iNKT Cell Therapy as a Potential Disease-Modifying Approach in Idiopathic Pulmonary Fibrosis at Keystone Symposia

Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPF Findings extend MiNK’s iNKT platform into chronic fibrotic lung disease and support immune restoration...

INKT : 10.73 (-5.38%)
MiNK Therapeutics and University of Wisconsin–Madison Announce Phase 1 Clinical Trial of Allo-iNKT Cell Therapy (AgenT-797) to Evaluate Prevention of Graft-Versus-Host Disease

Non-dilutive public-private funded trial with NIAID STTR & Mary Gooze Clinical Trial and Translation Award Expands iNKT platform into transplantation with an off-the-shelf, HLA-independent, lymphodepletion-free...

INKT : 10.73 (-5.38%)
MiNK Therapeutics Announces New Data Showing MiNK-215 Drives Potent Anti-Tumor Activity in Treatment-resistant Solid Tumors

MiNK-215, an IL-15 armoured FAP-targeting CAR-iNKT, targets and clears tumor-protective FAP+ fibroblasts to allow immune cells to infiltrate and kills cancer cells Activates multiple immune pathways...

INKT : 10.73 (-5.38%)

Business Summary

MiNK Therapeutics Inc. is a clinical stage biotechnology company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T cell therapies to treat cancer and other immune-mediated diseases. MiNK Therapeutics Inc. is headquartered in New York....

See More

Key Turning Points

3rd Resistance Point 12.38
2nd Resistance Point 12.17
1st Resistance Point 11.75
Last Price 10.73
1st Support Level 11.13
2nd Support Level 10.92
3rd Support Level 10.50

See More

52-Week High 76.00
Fibonacci 61.8% 49.39
Fibonacci 50% 41.17
Fibonacci 38.2% 32.95
Last Price 10.73
52-Week Low 6.34

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.